FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221106391> ?p ?o ?g. }

• W4221106391 endingPage "07" @default.
• W4221106391 startingPage "P5" @default.
• W4221106391 abstract "Abstract Background: Black women have higher incidence rates of TNBC and may experience worse clinical outcomes compared with White women with TNBC, due to disparities, comorbidities, or differences in TNBC biology (Dietze EG, et al. Nat Rev Cancer. 2015;15:248-254). As a result, Black pts with TNBC may benefit from novel therapies to improve outcomes. SG is an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to the cytotoxic SN-38 payload via a proprietary, hydrolyzable linker. SG received FDA approval for pts with mTNBC who received ≥2 prior chemotherapies (at least 1 in the metastatic setting). The confirmatory phase 3 ASCENT study (NCT02574455) in pts treated in second line or greater (2L+) mTNBC setting demonstrated a significant survival benefit of SG over single-agent chemotherapy treatment of physician’s choice (TPC; median progression-free survival, [PFS]: 4.8 vs 1.7 mo, HR 0.43, P&lt;0.001; median overall survival [OS]: 11.8 vs 6.9 mo, HR 0.51) in the full trial population, with a manageable safety profile. To better understand the clinical outcomes of Black pts in the ASCENT study, a subgroup analysis was performed. Methods: In ASCENT, pts with mTNBC refractory to or relapsing after ≥2 prior chemotherapies (at least 1 in the metastatic setting) were randomized 1:1 to receive SG (10 mg/kg IV on days 1 and 8, every 21 days) or TPC (capecitabine, eribulin, vinorelbine, or gemcitabine). Primary endpoint was PFS per RECIST 1.1 by independent review in brain metastases-negative pts. Secondary endpoints included OS, objective response rate (ORR), clinical benefit rate (CBR), and safety. Race was self-reported and a prespecified subgroup for efficacy analyses. In this subgroup analysis, efficacy outcomes were assessed in the full trial population (including pts with and without known brain metastases) of pts reporting Black race; safety was analyzed in pts who received ≥1 dose of study drug in this subgroup. Results: Of the 529 pts in the full trial population, 62 (12%) pts who received SG (n=28) or TPC (n=34) were Black pts (median age, 54 y [range, 32-75] with a median of 4 prior anticancer regimens [range, 2-10]; 2 pts (3%) were positive for BRCA1/2 mutations). Characteristics were generally balanced across treatment arms. Median duration of treatment was 5.3 vs 1.6 mo in the SG vs TPC arms, respectively. In this subgroup, median PFS was improved with SG vs TPC (5.4 vs 2.2 mo; HR, 0.44; 95% CI, 0.24-0.80; P=0.008) as were ORR (32% vs 6%; odds ratio, 7.6; 95% CI, 1.5-38.8; P=0.008) and CBR (43% vs 15%; odds ratio, 4.4; 95% CI, 1.3-14.6; P=0.014). Median OS was numerically longer with SG vs TPC (13.8 vs 8.5 mo; HR, 0.64; 95% CI, 0.34-1.19; P=0.159). The safety profile of SG in Black pts was similar to that of the full trial population. Key treatment-related adverse events (TRAEs) of grade ≥3 in this subgroup (SG vs TPC) were neutropenia (48% vs 42%), anemia (12% vs 6%), leukopenia (8% vs 16%), and febrile neutropenia (8% vs 3%). No pts in the SG arm discontinued due to TRAEs; 1 pt in the TPC (3%) arm discontinued due to TRAEs. There were no treatment-related deaths. Conclusions: While only 12% of pts in the ASCENT trial self-identified as Black, Black pts with pretreated mTNBC derived a similar clinical benefit from SG over TPC as seen in the full trial population, with a manageable safety profile. SG should be considered as a treatment option for pts with mTNBC in the 2L+ setting. Citation Format: Lisa A. Carey, Amelia Zelnak, Hope S. Rugo, Florence Dalenc, Rita Nanda, Michael Danso, Mahasti Saghatchian, Kevin Kalinsky, Nelly Firmin, Manuel Ruiz-Borrego, Anne Favret, Jun Sun, Lee Schwartzberg, Christie Hilton, Coral Omene, Robyn Young, Sara A. Hurvitz, Eliza Harting, See Phan, Aditya Bardia. Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-16-07." @default.
• W4221106391 created "2022-04-03" @default.
• W4221106391 creator A5005007467 @default.
• W4221106391 creator A5008527277 @default.
• W4221106391 creator A5016507388 @default.
• W4221106391 creator A5018045003 @default.
• W4221106391 creator A5034972183 @default.
• W4221106391 creator A5037214360 @default.
• W4221106391 creator A5038095983 @default.
• W4221106391 creator A5040945321 @default.
• W4221106391 creator A5042549514 @default.
• W4221106391 creator A5045301167 @default.
• W4221106391 creator A5052268581 @default.
• W4221106391 creator A5058791215 @default.
• W4221106391 creator A5061388899 @default.
• W4221106391 creator A5061450188 @default.
• W4221106391 creator A5068059897 @default.
• W4221106391 creator A5068911982 @default.
• W4221106391 creator A5072563567 @default.
• W4221106391 creator A5076092849 @default.
• W4221106391 creator A5076486609 @default.
• W4221106391 creator A5090188675 @default.
• W4221106391 date "2022-02-15" @default.
• W4221106391 modified "2023-10-11" @default.
• W4221106391 title "Abstract P5-16-07: Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)" @default.
• W4221106391 doi "https://doi.org/10.1158/1538-7445.sabcs21-p5-16-07" @default.
• W4221106391 hasPublicationYear "2022" @default.
• W4221106391 type Work @default.
• W4221106391 citedByCount "0" @default.
• W4221106391 crossrefType "journal-article" @default.
• W4221106391 hasAuthorship W4221106391A5005007467 @default.
• W4221106391 hasAuthorship W4221106391A5008527277 @default.
• W4221106391 hasAuthorship W4221106391A5016507388 @default.
• W4221106391 hasAuthorship W4221106391A5018045003 @default.
• W4221106391 hasAuthorship W4221106391A5034972183 @default.
• W4221106391 hasAuthorship W4221106391A5037214360 @default.
• W4221106391 hasAuthorship W4221106391A5038095983 @default.
• W4221106391 hasAuthorship W4221106391A5040945321 @default.
• W4221106391 hasAuthorship W4221106391A5042549514 @default.
• W4221106391 hasAuthorship W4221106391A5045301167 @default.
• W4221106391 hasAuthorship W4221106391A5052268581 @default.
• W4221106391 hasAuthorship W4221106391A5058791215 @default.
• W4221106391 hasAuthorship W4221106391A5061388899 @default.
• W4221106391 hasAuthorship W4221106391A5061450188 @default.
• W4221106391 hasAuthorship W4221106391A5068059897 @default.
• W4221106391 hasAuthorship W4221106391A5068911982 @default.
• W4221106391 hasAuthorship W4221106391A5072563567 @default.
• W4221106391 hasAuthorship W4221106391A5076092849 @default.
• W4221106391 hasAuthorship W4221106391A5076486609 @default.
• W4221106391 hasAuthorship W4221106391A5090188675 @default.
• W4221106391 hasConcept C121608353 @default.
• W4221106391 hasConcept C126322002 @default.
• W4221106391 hasConcept C143998085 @default.
• W4221106391 hasConcept C203092338 @default.
• W4221106391 hasConcept C2775930923 @default.
• W4221106391 hasConcept C2776387010 @default.
• W4221106391 hasConcept C2776694085 @default.
• W4221106391 hasConcept C2778239845 @default.
• W4221106391 hasConcept C2780110267 @default.
• W4221106391 hasConcept C2780258809 @default.
• W4221106391 hasConcept C2780350996 @default.
• W4221106391 hasConcept C2908647359 @default.
• W4221106391 hasConcept C31760486 @default.
• W4221106391 hasConcept C530470458 @default.
• W4221106391 hasConcept C535046627 @default.
• W4221106391 hasConcept C61943457 @default.
• W4221106391 hasConcept C71924100 @default.
• W4221106391 hasConcept C99454951 @default.
• W4221106391 hasConceptScore W4221106391C121608353 @default.
• W4221106391 hasConceptScore W4221106391C126322002 @default.
• W4221106391 hasConceptScore W4221106391C143998085 @default.
• W4221106391 hasConceptScore W4221106391C203092338 @default.
• W4221106391 hasConceptScore W4221106391C2775930923 @default.
• W4221106391 hasConceptScore W4221106391C2776387010 @default.
• W4221106391 hasConceptScore W4221106391C2776694085 @default.
• W4221106391 hasConceptScore W4221106391C2778239845 @default.
• W4221106391 hasConceptScore W4221106391C2780110267 @default.
• W4221106391 hasConceptScore W4221106391C2780258809 @default.
• W4221106391 hasConceptScore W4221106391C2780350996 @default.
• W4221106391 hasConceptScore W4221106391C2908647359 @default.
• W4221106391 hasConceptScore W4221106391C31760486 @default.
• W4221106391 hasConceptScore W4221106391C530470458 @default.
• W4221106391 hasConceptScore W4221106391C535046627 @default.
• W4221106391 hasConceptScore W4221106391C61943457 @default.
• W4221106391 hasConceptScore W4221106391C71924100 @default.
• W4221106391 hasConceptScore W4221106391C99454951 @default.
• W4221106391 hasIssue "4_Supplement" @default.
• W4221106391 hasLocation W42211063911 @default.
• W4221106391 hasOpenAccess W4221106391 @default.
• W4221106391 hasPrimaryLocation W42211063911 @default.
• W4221106391 hasRelatedWork W1972534072 @default.
• W4221106391 hasRelatedWork W2080459294 @default.
• W4221106391 hasRelatedWork W2135797559 @default.
• W4221106391 hasRelatedWork W2168708405 @default.
• W4221106391 hasRelatedWork W2739747635 @default.
• W4221106391 hasRelatedWork W2781769372 @default.
• W4221106391 hasRelatedWork W3196238380 @default.
• W4221106391 hasRelatedWork W4205733538 @default.

• next